- Licensed anti-HIV drugs
- Discontinued anti-HIV drugs
- Experimental anti-HIV drugs and treatments
- Alovudine
- ALVAC 1433
- AMD070
- AV-1101
- AVX754
- Azodicarbonamide (ADA)
- BMS-488043
- Brecanavir
- Buspirone hydrochloride (Buspar)
- Calanolide A
- Calcium spirulan
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvucitabine
- Etravirine
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GS 9137
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- Maraviroc
- MIV 150
- MK-0518
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- PA-457
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 542
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- T-1249
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
- Herbal and naturopathic treatments
- Failed anti-HIV drugs
Experimental anti-HIV drugs and treatments
- Alovudine
- ALVAC 1433
- AMD070
- AV-1101
- AVX754
- Azodicarbonamide (ADA)
- BMS-488043
- Brecanavir
- Buspirone hydrochloride (Buspar)
- Calanolide A
- Calcium spirulan
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvucitabine
- Etravirine
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GS 9137
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- Maraviroc
- MIV 150
- MK-0518
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- PA-457
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 542
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- T-1249
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research